ASCO 2020-话题@MedSci

#ASCO 2020#

32篇内容 | 1983人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1344248, encodeId=fdb7134424876, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020丨陈洁教授：纵使微小，也需努力前行，ASCO上NETs相关研究, objectType=article, longId=196206, objectId=552119620647, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=552119620647, replyNumber=0, likeNumber=74, createdTime=2020-06-22, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=552119620647, moduleTitle=ASCO 2020丨陈洁教授：纵使微小，也需努力前行，ASCO上NETs相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=552119620647)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344247, encodeId=ff5c134424e1c, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020 | 后起之秀：靶向PD-L1的前体治疗药物CX-072, objectType=article, longId=195529, objectId=cb091955294a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb091955294a, replyNumber=0, likeNumber=83, createdTime=2020-06-11, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb091955294a, moduleTitle=ASCO 2020 | 后起之秀：靶向PD-L1的前体治疗药物CX-072, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb091955294a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344246, encodeId=700f1344246bd, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%, objectType=article, longId=195492, objectId=c5e419549231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e419549231, replyNumber=0, likeNumber=80, createdTime=2020-06-10, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e419549231, moduleTitle=ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e419549231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344245, encodeId=b136134424506, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020 | 无处不在的曲妥珠单抗, objectType=article, longId=195360, objectId=5fa919536006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fa919536006, replyNumber=0, likeNumber=74, createdTime=2020-06-07, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fa919536006, moduleTitle=ASCO 2020 | 无处不在的曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fa919536006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344244, encodeId=8d0713442443e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, objectType=article, longId=195301, objectId=db5919530147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db5919530147, replyNumber=0, likeNumber=106, createdTime=2020-06-06, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db5919530147, moduleTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db5919530147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344243, encodeId=d71513442435f, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=80, createdTime=2020-06-06, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344242, encodeId=37331344242ff, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020丨遗憾！早期局部治疗未能改善原发IV期乳腺癌女性的总生存率, objectType=article, longId=195299, objectId=c885195299eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c885195299eb, replyNumber=0, likeNumber=95, createdTime=2020-06-06, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c885195299eb, moduleTitle=ASCO 2020丨遗憾！早期局部治疗未能改善原发IV期乳腺癌女性的总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c885195299eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344241, encodeId=bbbf13442416c, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, objectType=article, longId=195229, objectId=29d0195229fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29d0195229fb, replyNumber=0, likeNumber=102, createdTime=2020-06-05, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29d0195229fb, moduleTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29d0195229fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344240, encodeId=3076134424055, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020丨儿童肿瘤精准治疗获得新助力！优先级算法可行性佳, objectType=article, longId=195228, objectId=ecef1952288d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecef1952288d, replyNumber=0, likeNumber=0, createdTime=2020-06-05, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecef1952288d, moduleTitle=ASCO 2020丨儿童肿瘤精准治疗获得新助力！优先级算法可行性佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecef1952288d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344239, encodeId=fade13442398f, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020 来了 | 前列腺癌领域重磅研究盘点, objectType=article, longId=195132, objectId=b8591951321a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8591951321a, replyNumber=0, likeNumber=79, createdTime=2020-06-03, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8591951321a, moduleTitle=ASCO 2020 来了 | 前列腺癌领域重磅研究盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8591951321a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344238, encodeId=7a6613442388a, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020 | 肺鳞癌免疫治疗新突破，百济神州展现中国“研”值, objectType=article, longId=195059, objectId=f74a195059c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f74a195059c2, replyNumber=0, likeNumber=88, createdTime=2020-06-02, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f74a195059c2, moduleTitle=ASCO 2020 | 肺鳞癌免疫治疗新突破，百济神州展现中国“研”值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f74a195059c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344237, encodeId=d6ea134423e8f, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威, objectType=article, longId=195028, objectId=3b871950281b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b871950281b, replyNumber=0, likeNumber=90, createdTime=2020-06-01, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b871950281b, moduleTitle=ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b871950281b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344236, encodeId=263513442362e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：低免疫毒副作用的PD-L1抗体令人叹服, objectType=article, longId=195027, objectId=24f119502e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24f119502e0a, replyNumber=0, likeNumber=81, createdTime=2020-06-01, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24f119502e0a, moduleTitle=ASCO 2020：低免疫毒副作用的PD-L1抗体令人叹服, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24f119502e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344235, encodeId=4c3e1344235af, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）, objectType=article, longId=195026, objectId=3746195026a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3746195026a6, replyNumber=0, likeNumber=122, createdTime=2020-06-01, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3746195026a6, moduleTitle=ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3746195026a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344234, encodeId=a625134423456, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：HR+/HER2-晚期乳腺癌内脏转移时治疗的选择？, objectType=article, longId=195022, objectId=3d631950226f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d631950226f, replyNumber=0, likeNumber=78, createdTime=2020-06-01, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d631950226f, moduleTitle=ASCO 2020：HR+/HER2-晚期乳腺癌内脏转移时治疗的选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d631950226f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344233, encodeId=00b3134423303, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：新辅助治疗是否改善可切除胰腺癌患者预后？, objectType=article, longId=195015, objectId=16171950156b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16171950156b, replyNumber=0, likeNumber=98, createdTime=2020-06-01, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16171950156b, moduleTitle=ASCO 2020：新辅助治疗是否改善可切除胰腺癌患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16171950156b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344232, encodeId=eccd134423229, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, objectType=article, longId=194712, objectId=cf45194e12da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf45194e12da, replyNumber=0, likeNumber=95, createdTime=2020-05-27, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf45194e12da, moduleTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf45194e12da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344231, encodeId=9e1d13442318e, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：3年或1年伊马替尼辅助治疗高危胃肠道间质瘤的10年随访结果, objectType=article, longId=194649, objectId=61e919464970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61e919464970, replyNumber=0, likeNumber=84, createdTime=2020-05-25, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61e919464970, moduleTitle=ASCO 2020：3年或1年伊马替尼辅助治疗高危胃肠道间质瘤的10年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61e919464970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344230, encodeId=cc3c1344230a2, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：将老年医学评估和管理整合到癌症护理中可改善生活质量，减少老年患者的住院率, objectType=article, longId=194647, objectId=8edd19464e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8edd19464e54, replyNumber=0, likeNumber=85, createdTime=2020-05-25, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8edd19464e54, moduleTitle=ASCO 2020：将老年医学评估和管理整合到癌症护理中可改善生活质量，减少老年患者的住院率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8edd19464e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344229, encodeId=e3f71344229e8, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：泰瑞沙在早中期NSCLC中的疗效将公布, objectType=article, longId=194646, objectId=99c1194646de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99c1194646de, replyNumber=0, likeNumber=82, createdTime=2020-05-25, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99c1194646de, moduleTitle=ASCO 2020：泰瑞沙在早中期NSCLC中的疗效将公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99c1194646de)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASCO 2020

2020-05-29

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020丨陈洁教授：纵使微小，也需努力前行，ASCO上NETs相关研究

2020-06-22

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020 | 后起之秀：靶向PD-L1的前体治疗药物CX-072

2020-06-11

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%

2020-06-10

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020 | 无处不在的曲妥珠单抗

2020-06-07

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位

2020-06-06

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2020-06-06

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020丨遗憾！早期局部治疗未能改善原发IV期乳腺癌女性的总生存率

2020-06-06

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相

2020-06-05

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020丨儿童肿瘤精准治疗获得新助力！优先级算法可行性佳

2020-06-05

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020 来了 | 前列腺癌领域重磅研究盘点

2020-06-03

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020 | 肺鳞癌免疫治疗新突破，百济神州展现中国“研”值

2020-06-02

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威

2020-06-01

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：低免疫毒副作用的PD-L1抗体令人叹服

2020-06-01

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）

2020-06-01

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：HR+/HER2-晚期乳腺癌内脏转移时治疗的选择？

2020-06-01

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：新辅助治疗是否改善可切除胰腺癌患者预后？

2020-06-01

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）

2020-05-27

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：3年或1年伊马替尼辅助治疗高危胃肠道间质瘤的10年随访结果

2020-05-25

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：将老年医学评估和管理整合到癌症护理中可改善生活质量，减少老年患者的住院率

2020-05-25

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：泰瑞沙在早中期NSCLC中的疗效将公布

2020-05-25

科室
- - 订阅+
  - 更多科室
工具
服务